



(12) Translation of
European patent specification

(11) NO/EP 3966207 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 403/12 (2006.01)

A61K 31/444 (2006.01)

A61K 31/506 (2006.01)

A61P 35/00 (2006.01)

C07D 403/14 (2006.01)

C07D 471/08 (2006.01)

C07D 487/04 (2006.01)


C07D 487/08 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.01.15
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.11.01
(86)	European Application Nr.	20729420.8
(86)	European Filing Date	2020.05.08
(87)	The European Application's Publication Date	2022.03.16
(30)	Priority	2019.05.10, US, 201962846251 P 2019.05.10, US, 201962846258 P 2019.10.07, US, 201962911728 P 2019.10.07, US, 201962911730 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
	Designated Extension States:	BA; ME
	Designated validation states	MA; TN
(73)	Proprietor	Deciphera Pharmaceuticals, LLC, 200 Smith Street, Waltham, MA 02451, USA
(72)	Inventor	FLYNN, Daniel, L., 4165 Blackjack Oak Drive, Lawrence, KS 66047, USA AHN, Yu, Mi, 200 Smith Street, Waltham, MA 02451, USA CALDWELL, Timothy, 200 Smith Street, Waltham, MA 02451, USA VOGETI, Lakshminarayana, 200 Smith Street, Waltham, MA 02451, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF
(56)	References Cited:	WO-A1-03/032997 WO-A1-2004/048343

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav**1.** En forbindelse representert av:

Formel I

eller et farmasøytisk akseptabelt salt, enantiomer, stereoisomer, eller tautomer derav, hvor:

15 W er CH eller N;

X er CH eller N;

Y er C(R³) eller N;

20 R¹ er valgt fra gruppen som består av halogen, cyano, C₁-C₅alkyl, og C₃-C₅sykloalkyl, hvor hver C₁-C₅alkyl og C₃-C₅sykloalkyl eventuelt kan være substituert med én, to eller tre uavhengige forekomster av fluor;

25 R² er valgt fra gruppen som består av H, halogen, cyano, C₁-C₅alkyl, C₃-C₆sykloalkyl, C₂-C₅alkenyl, C₂-C₅alkynyl, C₁-C₅alkoksy, og C₁-C₅alkoksy-C₂-C₅alkyl, hvor hver C₁-C₅alkyl, C₃-C₆sykloalkyl, C₂-C₅alkenyl, C₂-C₅alkynyl, og C₁-C₅alkoksy eventuelt kan være substituert med én, to eller tre uavhengige forekomster av fluor eller cyano;

hver forekomst av R³ og R³³ er uavhengig valgt fra gruppen som består av H, halogen, C₁-C₆alkyl, og C₁-C₆alkoksy, hvor hver C₁-C₆alkyl og C₁-C₆alkoksy eventuelt kan være substituert med én eller flere uavhengige forekomster av fluor;

30 R⁴ er valgt fra gruppen som består av B, D, NR⁶R⁹, NR⁶-(C(R¹⁰)₂)_p-NR⁹R⁹, C(O)-NR⁶R⁹, C(O)-B, C(O)-D, og CN;

B er valgt fra en N-bundet heterosyklyl som har minst ett nitrogen og eventuelt som har et ytterligere ringnitrogen eller oksygen og heteroaryl,

hvor B eventuelt kan være substituert på ett eller flere tilgjengelige karboner med R^7 og eventuelt kan være substituert på et tilgjengelig nitrogen med R^9 ;

5 D er valgt fra en C-bundet heterosyklyl som har minst ett nitrogen og eventuelt som har et ytterligere ringnitrogen eller oksygen og heteroaryl, hvor D eventuelt kan være substituert på ett eller flere tilgjengelige karboner med R^7 og eventuelt kan være substituert på et tilgjengelig nitrogen med R^9 ;

10 hver forekomst av R^7 er uavhengig valgt fra gruppen som består av H, C_1 - C_6 alkyl, C_3 - C_6 sykloalkyl, cyano, og $(C(R^{10})_2)_h-NR^9R^9$, hvor hver C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl eventuelt kan være substituert med én eller flere uavhengige forekomster av fluor, eller to R^7 er koblet sammen med atomet som de er festet til for å danne okso;

15 hver forekomst av R^6 og R^9 er uavhengig valgt fra gruppen som består av H, C_1 - C_6 alkyl, C_3 - C_6 sykloalkyl, C_1 - C_5 alkoksy- C_2 - C_5 alkyl, $C(=O)R^5$, SO_2R^5 , og C-bundet heterosyklyl som har minst ett nitrogen og eventuelt som har et ytterligere ringnitrogen eller oksygen, og heteroaryl, hvor hver C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl eventuelt kan være substituert med én eller flere uavhengige forekomster av fluor;

20 hver forekomst av R^5 er uavhengig valgt fra gruppen som består av H, C_1 - C_6 alkyl, C_3 - C_6 sykloalkyl, og heterosyklyl, hvor hver C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl eventuelt kan være substituert med én eller flere uavhengige forekomster av fluor;

25 hver forekomst av R^{10} er uavhengig valgt fra gruppen som består av H, C_1 - C_3 alkyl, og C_3 - C_5 sykloalkyl, hvor hver C_1 - C_3 alkyl og C_3 - C_5 sykloalkyl eventuelt kan være substituert med én eller flere uavhengige forekomster av fluor, eller to R^{10} er koblet sammen med karbonet som de er festet til for å danne en C_3 - C_5 sykloalkyl;

30 Z er valgt fra gruppen som består av en 4-leddet laktamring bundet gjennom nitrogenatomet og en 6-10-leddet laktamring bundet gjennom nitrogenatomet, hvor et laktamring-atom eventuelt kan være oksygen eller NR^6 når laktamringen er en 6-10-leddet ring og et tilgjengelige karbonatom

på en 4-leddet laktamring eller en 6-10-leddet laktamring er eventuelt substituert med R^{36} ,

hver forekomst av R^{36} er uavhengig valgt fra C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl,

hvor hver C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl eventuelt kan være substituert med

én eller flere uavhengige forekomster av fluor, eller to R^{36} er koblet

sammen med karbonet som de er festet til for å danne en C_3 - C_6 sykloalkyl;

h er 1, 2, eller 3;

m er 0, 1, 2, eller 3;


n er 2, 3, eller 4; og

p er 2 eller 3;

forutsatt at både X og Y ikke er N.

2. Forbindelsen ifølge krav 1, hvor Z er valgt fra:

(i)



hvor

V er valgt fra gruppen som består av oksygen, $C(R^{34})_2$, og NR^6 ;


hver forekomst av R^{34} er uavhengig valgt fra H og R^{36} , hvor hver forekomst av R^{36} er uavhengig valgt fra C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl, eller to R^{36} er koblet sammen med karbonet som de er festet til for å danne en C_3 - C_6 sykloalkyl;

q er 0, 1, 2, eller 3; og

r er 2 eller 4;

forutsatt at, hvis q er 0, så er r ikke 2; eller

(ii)



hvor


V er valgt fra gruppen som består av oksygen, $C(R^{34})_2$, og NR^6 ;

hver forekomst av R^{34} er uavhengig valgt fra H og R^{36} , hvor hver forekomst av R^{36} er uavhengig valgt fra C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl, eller to R^{36} er koblet sammen med karbonet som de er festet til for å danne en C_3 - C_6 sykloalkyl;

q er 0, 1, 2, eller 3; og


r er 2 eller 3;


forutsatt at, hvis q er 0, så er r ikke 2, for eksempel hvor Z er valgt fra gruppen som består av




3. Forbindelsen ifølge krav 1 eller krav 2, hvor:

R^4 er valgt fra gruppen som består av





5



hvor u er 1 eller 2; og/eller

10

R^1 er valgt fra gruppen som består av halogen, C_1 - C_5 alkyl, og C_3 - C_5 sykloalkyl, hvor C_1 - C_5 alkyl eventuelt kan være substituert med én, to eller tre forekomster av fluor; og/eller


R^2 er valgt fra gruppen som består av C_1 -2alkyl, C_3 -4sykloalkyl, klor og brom; og/eller

n er 3.

15

4. Forbindelsen ifølge krav 1, representert av:

20




Formel II

25

eller et farmasøytisk akseptabelt salt derav, hvor:

Z er valgt fra gruppen som består av




5

R^2 er valgt fra gruppen som består av halogen, C_1 - C_2 alkyl og C_3 - C_4 sykloalkyl;

R^4 er valgt fra gruppen som består av

10



15

hver forekomst av R^6 og R^9 er uavhengig valgt fra gruppen som består av H, C_1 - C_6 alkyl, C_3 - C_6 sykloalkyl, $C(=O)R^5$, SO_2R^5 , og C-bundet heterosyklyl som har minst ett nitrogen og eventuelt som har et ytterligere ringnitrogen eller oksygen, og heteroaryl, hvor hver C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl eventuelt kan være substituert med én eller flere uavhengige forekomster av fluor;

20

hver forekomst av R^7 er uavhengig valgt fra gruppen som består av H, C_1 - C_6 alkyl, og C_3 - C_6 sykloalkyl, hvor hver C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl eventuelt kan være substituert med én eller flere uavhengige forekomster av fluor, eller to R^7 er koblet sammen med atomet som de er festet til for å danne okso; og

25

hver forekomst av R^{34} er uavhengig valgt fra H og R^{36} , hvor hver forekomst av R^{36} er uavhengig valgt fra C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl, hvor hver C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl eventuelt kan være substituert med én eller flere uavhengige forekomster av fluor, eller to R^{36} er koblet sammen med karbonet som de er festet til for å danne en C_3 - C_6 sykloalkyl.


30

5. Forbindelsen ifølge krav 4, hvor:

R^1 er valgt fra gruppen som består av halogen, C_1 - C_5 alkyl, og C_3 - C_5 sykloalkyl, hvor C_1 - C_5 alkyl kan eventuelt være substituert med én, to eller tre forekomster av fluor, for eksempel CF_3 ; og/eller



R^2 er valgt fra gruppen som består av H, C_3 - C_4 sykloalkyl, C_1 - C_5 alkyl, og halogen; og/eller

R^4 er valgt fra gruppen som består av




og/eller

Z er valgt fra gruppen som består av:



og




og/eller

hver forekomst av R^6 og R^9 er uavhengig valgt fra gruppen som består av H, C_1 - C_6 alkyl, og C_3 - C_6 sykloalkyl, hvor hver av C_1 - C_6 alkyl og C_3 - C_6 sykloalkyl er eventuelt substituert med én eller flere uavhengige forekomster av fluor.

6. Forbindelsen ifølge krav 1 representert av:

(i)




10 hvor

R^1 er valgt fra gruppen som består av CF_3 , CF_2H , brom, klor, og syklopropyl;

R^2 er valgt fra gruppen som består av C_1 - C_2 alkyl, C_3 - C_4 sykloalkyl, og halogen; og

R^9 er valgt fra gruppen som består av C_1 - C_3 alkyl, H, og C_3 - C_5 sykloalkyl; eller

(ii)



Formel IIA.11-A

30 hvor

R^1 er valgt fra gruppen som består av brom, klor, CF_3 , CF_2H , og syklopropyl;

R^2 er valgt fra gruppen som består av C_1 - C_2 alkyl, C_3 - C_4 sykloalkyl, og halogen; og

R^9 er valgt fra gruppen som består av C_1 - C_3 alkyl, H, og C_3 - C_5 sykloalkyl.

- 5 **7.** Forbindelsen ifølge krav 6, hvor R^1 er CF_3 ; R^2 er valgt fra gruppen som består av C_1 - C_2 alkyl, C_3 - C_4 sykloalkyl, brom, og klor; og R^9 er valgt fra C_1 - C_3 alkyl og H.
- 8.** Forbindelsen ifølge krav 1 valgt fra gruppen som består av 1-(3-((5-brom-2-((2-syklopropyl-4-(4-metyl piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)piperidin-2-on,
- 10 1-(3-((2-((4-(4-etyl piperazin-1-yl)-2-metyl fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 1-(3-((5-klor-2-((2-syklopropyl-4-(4-metyl piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 15 1-(3-((2-((2-syklopropyl-4-(4-metyl-1,4-diazepan-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 1-(3-((5-klor-2-((2-metyl-4-(1-metyl piperidin-4-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)piperidin-2-on,
- (R)-1-(3-etyl-4-((4-((3-(2-oksopiperidin-1-yl)propyl)amino)-5-(trifluormetyl)pyrimidin-2-yl)amino)fenyl)pyrrolidin-3-karbonitril,
- 20 1-(3-((2-((4-(4-syklopropyl piperazin-1-yl)-2-metyl fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 1-(3-((5-brom-2-((2-isopropyl-4-(4-metyl piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 25 1-(3-((2-((2-etyl-4-(4-etyl piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)-amino)propyl)piperidin-2-on,
- 1-(3-((2-((2-syklopropyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 4-(3-syklopropyl-4-((4-((3-(2-oksopiperidin-1-yl)propyl)amino)-5-(trifluormetyl)-pyrimidin-2-yl)amino)fenyl)-1-metyl piperazin-2-on,
- 30 1-(3-((5-brom-2-((4-(4-etyl piperazin-1-yl)-2-isopropyl fenyl)amino)pyrimidin-4-yl)-amino)propyl)piperidin-2-on,

- 1-(3-((2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)-amino)propyl)piperidin-2-on,
- 1-(3-((2-((2-metyl-4-(1-metyl piperidin-4-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 5 1-(3-((5-klor-2-((4-(4-etyl piperazin-1-yl)-2-isopropylfenyl)amino)pyrimidin-4-yl)-amino)propyl)piperidin-2-on,
- 1-(3-((2-((2-syklopropyl-4-(piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)-amino)propyl)piperidin-2-on,
- 1-(3-((2-((2-syklopropyl-5-fluor-4-(4-metyl piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 10 1-(3-((2-((2-metyl-4-(piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 1-(3-((2-((2-metyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 15 1-(3-((2-((4-(4-(2-fluoretyl)piperazin-1-yl)-2-metylfenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 1-(3-((5-klor-2-((2-metyl-4-(piperidin-4-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)piperidin-2-on,
- 1-(3-((2-((4-(4-acetyl piperazin-1-yl)-2-syklopropylfenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 20 1-(3-((5-klor-2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)piperidin-2-on,
- (S)-1-(3-etyl-4-((4-((3-(2-oksopiperidin-1-yl)propyl)amino)-5-(trifluormetyl)pyrimidin-2-yl)amino)fenyl)pyrrolidin-3-karbonitril,
- 25 1-(3-((5-brom-2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)piperidin-2-on,
- 1-(3-((2-((4-(4-isopropyl piperazin-1-yl)-2-metylfenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 1-(3-((2-((2-isopropyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 30 1-(3-((2-((4-(4-syklobutyl piperazin-1-yl)-2-metylfenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,

- 1-(3-((2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 1-(3-((2-((2-syklopropyl-4-(4-etyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 5 1-(3-((2-((2-metyl-4-(piperidin-4-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)-propyl)piperidin-2-on,
- 1-(3-((2-((4-(1,4-diazepan-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)-propyl)piperidin-2-on,
- 1-(3-((2-((2-etyl-4-(4-metyl-1,4-diazepan-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 10 1-(3-((2-((4-(4-etyl)piperazin-1-yl)-2-isopropylfenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 1-(3-((2-((4-(4-etyl-1,4-diazepan-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)-amino)propyl)piperidin-2-on,
- 15 1-(3-((2-((4-metyl-6-morfolinopyridin-3-yl)amino)-5-(trifluormetyl)pyrimidin-4-yl)-amino)propyl)piperidin-2-on,
- 3-(3-((2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 3-(3-((2-((2-syklopropyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 20 3-(3-((5-klor-2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)-1,3-oksazinan-2-on,
- 3-(3-((5-brom-2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)-1,3-oksazinan-2-on,
- 25 3-(3-((5-syklopropyl-2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)-amino)propyl)-1,3-oksazinan-2-on,
- 3-(3-((2-((2-etyl-4-(piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)-propyl)-1,3-oksazinan-2-on,
- 3-(3-((2-((2-syklopropyl-4-(piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)-amino)propyl)-1,3-oksazinan-2-on,
- 30 3-(3-((5-brom-2-((2-syklopropyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)-amino)propyl)-1,3-oksazinan-2-on,

- 3-(3-((2-((2-metyl-4-(piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)-amino)propyl)-1,3-oksazinan-2-on,
- 3-(3-((2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 5 rac-(R)-3-(3-((2-((2-etyl-4-(heksahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- rac-(R)-3-(3-((2-((2-syklopropyl-4-(heksahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 3-(3-((2-((2-etyl-4-(4-metyl-2-oksopiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 10 3-(3-((2-((2-metyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 4-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)morfolin-3-on,
- 15 1-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)azepan-2-on,
- 4-(3-((2-((2-etyl-4-morfolinofenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((2-((2-syklopropyl-4-morfolinofenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 20 4-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-3-on,
- 25 4-(3-((5-klor-2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((5-klor-2-((2-etyl-4-morfolinofenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((5-klor-2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)-amino)-propyl)-1,4-oksazepan-3-on,
- 30 4-(3-((5-klor-2-((2-syklopropyl-4-morfolinofenyl)amino)pyrimidin-4-yl)amino)-propyl)-1,4-oksazepan-3-on,

- 4-(3-((2-((4-(4-ethylpiperazin-1-yl)-2-isopropylfenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((5-syklopropyl-2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-3-on,
- 5 4-(3-((2-((2-syklopropyl-4-(piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((2-((2-etyl-4-(4-metyl-1,4-diazepan-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((2-((2-etyl-5-fluor-4-(4-metyl piperazin-1-yl)fenyl)amino)-5-(trifluor-
- 10 metyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((5-brom-2-((2-syklopropyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((5-brom-2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)-1,4-oksazepan-3-on,
- 15 4-(3-((5-brom-2-((2-isopropyl-4-(4-metyl piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((2-((2-metyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-
- 20 pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-syklopropyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-5-(trifluor-metyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-syklopropyl-4-morfolinofenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 25 4-(3-((2-((2-etyl-4-morfolinofenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((4-(4-ethylpiperazin-1-yl)-2-isopropylfenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-metyl-4-(piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-
- 30 yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((5-brom-2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)-1,4-oksazepan-5-on,

- rac-4-(3-((2-((4-((1R,4R)-2-oksa-5-azabisyklo[2.2.1]heptan-5-yl)-2-metylfenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-etyl-4-(4-metyl-1,4-diazepan-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 5 4-(3-((5-klor-2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)-1,4-oksazepan-5-on,
- 4-(3-((5-brom-2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
- 10 4-(3-((5-klor-2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((5-syklopropyl-2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-etyl-4-(piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)-propyl)-1,4-oksazepan-5-on,
- 15 4-(3-((2-((2-syklopropyl-4-(piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-etyl-5-fluor-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 20 4-(3-((5-brom-2-((2-isopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((5-klor-2-((2-isopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((5-klor-2-((2-syklopropyl-4-(piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)-propyl)-1,4-oksazepan-5-on,
- 25 4-(3-((2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- rac-(R)-4-(3-((2-((2-etyl-4-(heksahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 30 1-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)piperidin-2-on,
- 4-(3-((2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,

- 4-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 3-(3-((2-((4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)-propyl)-1,3-oksazinan-2-on,
 5 1-(3-((2-((4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)-propyl)piperidin-2-on,
 1-(3-((2-((4-metyl-6-(4-metylpiperazin-1-yl)pyridin-3-yl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)piperidin-2-on,
 1-(3-((2-((4-metyl-6-morfolinopyridin-3-yl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)-propyl)piperidin-2-on,
 10 4-(3-((5-klor-2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyridin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
 1-(3-((2-((4-metyl-6-(4-metylpiperazin-1-yl)pyridin-3-yl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)piperidin-2-on,
 15 1-(3-((2-((5-(4-metylpiperazin-1-yl)pyridin-2-yl)amino)-5-(trifluormetyl)pyridin-4-yl)-amino)propyl)piperidin-2-on,
 4-(3-((2-((4-etyl-6-(4-metylpiperazin-1-yl)pyridin-3-yl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
 4-(3-((2-((4-etyl-6-(4-metylpiperazin-1-yl)pyridin-3-yl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 20 (R)-4-(3-((2-((2-syklopropyl-4-(heksahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 4-(3-((2-((2-etyl-4-((1S,4S)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 25 3-(3-((2-((2-etyl-4-((1S,4S)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 4-(3-((2-((2-syklopropyl-4-((1S,4S)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 30 3-(3-((2-((2-syklopropyl-4-((1S,4S)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)-fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,

- 4-(3-((2-((2-etyl-4-((1R,4R)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 4-(3-((2-((2-syklopropyl-4-((1R,4R)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 5 on,
 3-(3-((2-((2-etyl-4-((1R,4R)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 3-(3-((2-((4-etyl-6-(4-metyl piperazin-1-yl)pyridin-3-yl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 10 2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-4-((3-(5-okso-1,4-oksazepan-4-yl)-propyl)amino)pyrimidin-5-karbonitril,
 3-(3-((2-((2-syklopropyl-4-((1R,4R)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 15 (4-(3-((5-(difluormetyl)-2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)-amino)-pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
 3-(3-((5-(difluormetyl)-2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 2-((2-etyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-4-((3-(2-okso-1,3-oksazinan-3-yl)-propyl)amino)pyrimidin-5-karbonitril,
 20 4-(3-((2-((2-etyl-4-(1-metyl piperidin-4-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
 4-(3-((2-((2-etyl-4-((1R,5S)-3-metyl-3,8-diazabisyklo[3.2.1]oktan-8-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 25 4-(3-((2-((2-etyl-4-(9-metyl-3,9-diazabisyklo[3.3.1]nonan-3-yl)fenyl)amino)-5-(trifluor-metyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 4-(3-((2-((2-etyl-4-(3-metyl-3,9-diazabisyklo[3.3.1]nonan-9-yl)fenyl)amino)-5-(trifluor-metyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 4-(3-((2-((2-etyl-4-(1-metyl pyrrolidin-3-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)-amino)propyl)-1,4-oksazepan-5-on,
 30 4-(3-((2-((2-etynyl-4-(4-metyl piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,

- 4-(3-((2-((2-(etylnyl-d)-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-(etyl-d5)-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 5 4-(3-((2-((4-(4-metylpiperazin-1-yl)-2-(2,2,2-trifluoretyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-(1,1-difluoretyl)-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 5-(4-metylpiperazin-1-yl)-2-((4-((3-(5-okso-1,4-oksazepan-4-yl)propyl)amino)-5-(trifluormetyl)pyrimidin-2-yl)amino)benzonitril,
- 10 2-metyl-2-(5-(4-metylpiperazin-1-yl)-2-((4-((3-(5-okso-1,4-oksazepan-4-yl)propyl)amino)-5-(trifluormetyl)pyrimidin-2-yl)amino)fenyl)propannitril,
- 2-(5-(4-metylpiperazin-1-yl)-2-((4-((3-(5-okso-1,4-oksazepan-4-yl)propyl)-amino)-5-(trifluormetyl)pyrimidin-2-yl)amino)fenyl)acetonitril,
- 15 4-(3-((2-((4-(4-metylpiperazin-1-yl)-2-(trifluormetyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-(difluormetyl)-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-brom-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 20 4-(3-((2-((2-klor-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-syklopropyl-4-(3-((dimetylamino)metyl)azetidin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 25 1-(3-((2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-3-metyltetrahydropyrimidin-2(1H)-on,
- 1-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-3-metyltetrahydropyrimidin-2(1H)-on,
- 3-3-((2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,3-oksazepan-2-on,
- 30 3-3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,3-oksazepan-2-on,

- 1-(3-((2-((2-etyl-4-(-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-4-metyl-1,4-diazepan-2-on,
- 1-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-4-metyl-1,4-diazepan-2-on,
- 5 4-(3-((2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1-metyl-1,4-diazepan-5-on,
- 4-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1-metyl-1,4-diazepan-5-on,
- 1-(3-((2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-3-metyl-1,3-diazepan-2-on,
- 10 1-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-3-metyl-1,3-diazepan-2-on,
- 3-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 15 3-(3-((5-(difluormetyl)-2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 3-(3-((2-((2-syklopropyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)-fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 20 3-(3-((5-(difluormetyl)-2-((2-etyl-4-((1S,4S)-5-metyl-2,5-diazabisyklo[2.2.1]-heptan-2-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 3-(3-((5-(difluormetyl)-2-((2-etyl-4-((1R,4R)-5-metyl-2,5-diazabisyklo[2.2.1]-heptan-2-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- (R)-3-(3-((5-(difluormetyl)-2-((2-etyl-4-(heksahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 25 (S)-3-(3-((5-(difluormetyl)-2-((2-etyl-4-(heksahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 3-(3-((5-(difluormetyl)-2-((2-etyl-4-(piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 30 3-(3-((2-((2-syklopropyl-4-(piperazin-1-yl)fenyl)amino)-5-(difluormetyl)-pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 1-(3-((5-(difluormetyl)-2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-pyrimidin-4-yl)amino)propyl)-3-metyl-tetrahydropyrimidin-2(1H)-on,

- 1-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(difluormetyl)-pyrimidin-4-yl)amino)propyl)-3-metyltetrahydropyrimidin-2(1H)-on,
 4-(3-((5-(difluormetyl)-2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)-amino)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
 5 4-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
 4-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 3-(3-((5-(difluormetyl)-2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oksazepan-2-on,
 10 3-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazepan-2-on,
 1-(3-((5-(difluormetyl)-2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-4-metyl-1,4-diazepan-2-on,
 15 1-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)-4-metyl-1,4-diazepan-2-on,
 4-(3-((5-(difluormetyl)-2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1-metyl-1,4-diazepan-5-on,
 4-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)-1-metyl-1,4-diazepan-5-on,
 20 1-(3-((5-(difluormetyl)-2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-3-metyl-1,3-diazepan-2-on,
 1-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)-3-metyl-1,3-diazepan-2-on,
 25 2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(2-okso-1,3-oksazinan-3-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-syklopropyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)-amino)-4-((3-(2-okso-1,3-oksazinan-3-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)-
 30 4-((3-(2-okso-1,3-oksazinan-3-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-etyl-4-((1S,4S)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)amino)-
 4-((3-(2-okso-1,3-oksazinan-3-yl)propyl)amino)pyrimidin-5-karbonitril,

- 2-((2-etyl-4-((1R,4R)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)amino)-4-((3-(2-okso-1,3-oksazinan-3-yl)propyl)amino)pyrimidin-5-karbonitril,
 (R)-2-((2-etyl-4-(heksahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)fenyl)amino)-4-((3-(2-okso-1,3-oksazinan-3-yl)propyl)amino)pyrimidin-5-karbonitril,
 5 (S)-2-((2-etyl-4-(heksahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)fenyl)amino)-4-((3-(2-okso-1,3-oksazinan-3-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-etyl-4-(piperazin-1-yl)fenyl)amino)-4-((3-(2-okso-1,3-oksazinan-3-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-syklopropyl-4-(piperazin-1-yl)fenyl)amino)-4-((3-(2-okso-1,3-oksazinan-3-yl)propyl)amino)pyrimidin-5-karbonitril,
 10 3-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(3-metyl-2-okso-tetrahydropyrimidin-1(2H)-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(3-metyl-2-okso-tetrahydropyrimidin-1(2H)-yl)propyl)amino)pyrimidin-5-karbonitril,
 15 2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(3-okso-1,4-oksazepan-4-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(3-okso-1,4-oksazepan-4-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(5-okso-1,4-oksazepan-4-yl)propyl)amino)pyrimidin-5-karbonitril,
 20 2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(2-okso-1,3-oksazepan-3-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(2-okso-1,3-oksazepan-3-yl)propyl)amino)pyrimidin-5-karbonitril,
 25 2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(4-metyl-2-okso-1,4-diazepan-1-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(4-metyl-7-okso-1,4-diazepan-1-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(4-metyl-7-okso-1,4-diazepan-1-yl)propyl)amino)pyrimidin-5-karbonitril,
 30 1,4-diazepan-1-yl)propyl)amino)pyrimidin-5-karbonitril,
 2-((2-etyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(3-metyl-2-okso-1,3-diazepan-1-yl)propyl)amino)pyrimidin-5-karbonitril,

- 2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-4-((3-(3-metyl-2-okso-1,3-diazepan-1-yl)propyl)amino)pyrimidin-5-karbonitril,
- 1-(3-((2-((2-syklopropyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 5 1-(3-((2-((2-syklopropyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 3-(3-((2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-6,6-dimetyl-1,3-oksazinan-2-on,
- 10 4-(3-((2-((2-syklopropyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-syklopropyl-4-(5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-
- 15 on,
- 4-(3-((5-(difluormetyl)-2-((2-etyl-4-(5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((5-(difluormetyl)-2-((2-etyl-4-((1R,5S)-8-metyl-3,8-
- 20 diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((5-(difluormetyl)-2-((2-etyl-4-(5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 25 4-(3-((2-((2-etyl-4-(5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 3-(3-((5-(difluormetyl)-2-((2-etyl-4-((1R,5S)-8-metyl-3,8-
- 30 diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-1,3-oksazepan-2-on,
- 3-(3-((2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazepan-2-on,

- 4-(3-((2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-6,6-dimetyl-1,4-oksazepan-5-on,
 3-(3-((2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-6,6-dimetyl-1,3-oksazinan-2-on,
- 5 4-(3-((2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-2,2-dimetyl-1,4-oksazepan-3-on,
- 4-(3-((2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-2,2-dimetyl-1,4-oksazepan-3-on,
- 10 4-(3-((5-(difluormetyl)-2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-6,6-dimetyl-1,4-oksazepan-5-on,
 8-(3-((2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-5-oksa-8-azaspiro[2.6]nonan-9-on,
- 4-(3-((2-((4-(1,4-diazabisyklo[3.2.1]oktan-4-yl)-2-etyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on, 4-(3-((2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-6,6-dimetyl-1,4-oksazepan-5-on,
- 15 4-(3-((5-(difluormetyl)-2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)pyrimidin-4-yl)amino)propyl)-6,6-dimetyl-1,4-oksazepan-5-on,
- 20 4-(3-((2-((4-(1,4-diazabisyklo[3.2.1]oktan-4-yl)-2-etyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-6,6-dimetyl-1,4-oksazepan-5-on,
 4-(3-((2-((4-(1,4-diazabisyklo[3.2.1]oktan-4-yl)-2-etyl)fenyl)amino)-5-(difluormetyl)pyrimidin-4-yl)amino)propyl)-6,6-dimetyl-1,4-oksazepan-5-on,
- 25 1-(3-((2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)azetidin-2-on,
- 1-(3-((2-((2-etyl-4-(4-metyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-3,3-dimetylazetidin-2-on,
- 1-(3-((2-((4-(1,4-diazabisyklo[3.2.1]oktan-4-yl)-2-etyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)azetidin-2-on,
- 30 1-(3-((2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)azetidin-2-on,

- 1-(3-((2-((2-etyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-3,3-dimetylazetidin-2-on,
 1-(3-((2-((4-(1,4-diazabisyklo[3.2.1]oktan-4-yl)-2-etylfenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-3,3-dimetylazetidin-2-on,
 5 1-(3-((2-((2-etyl-4-(heksahidropyrrolo[1,2-a]pyrazin-2(1H)-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)azetidin-2-on,
 1-(3-((2-((2-etyl-4-(heksahidropyrrolo[1,2-a]pyrazin-2(1H)-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-3,3-dimetylazetidin-2-on,
 1-(3-((2-((2-etyl-4-(5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)amino)-5-
 10 (trifluormetyl)pyrimidin-4-yl)amino)propyl)azetidin-2-on,
 1-(3-((2-((2-etyl-4-(5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-3,3-dimetylazetidin-2-on,
 1-(3-((2-((2-etyl-4-(5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)pyrrolidin-2-on,
 15 4-(3-((2-((4-(3-(dietylamo)propyl)-2-etylfenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 4-(3-((2-((2-syklopropyl-4-(3-morfolinopropyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
 3-(3-((2-((2-etyl-4-(2-(pyrrolidin-1-yl)etyl)fenyl)amino)-5-
 20 (trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 3-(3-((2-((2-syklopropyl-4-((dimetylamo)metyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 3-(3-((2-((2-syklopropyl-4-(4-metyl piperazine-1-karbonyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 25 3-metoksy-N-(1-metyl piperidin-4-yl)-4-((4-((3-(5-okso-1,4-oksazepan-4-yl)propyl)amino)-5-(trifluormetyl)pyrimidin-2-yl)amino)benzamid,
 1-(3-((2-((2-syklopropyl-4-(morfolinometyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
 1-(3-((2-((2-etyl-4-(2-(pyrrolidin-1-yl)propan-2-yl)fenyl)amino)-5-
 30 (trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
 4-(3-((2-((2-etyl-4-(2-(4-metyl piperazin-1-yl)-2-oksoetyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,

- 4-(3-((2-((4-(4-((dimetylamino)metyl)piperidin-1-yl)-2-etylfenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((4-(3,3-dimetylpiperazin-1-yl)-2-etylfenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 5 4-(3-((2-((2-etyl-4-(3,3,5,5-tetrametylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((2-((2-syklopropyl-4-(3,4,5-trimetylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-etyl-4-(3,3,4-trimetylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 10 4-(3-((2-((2-etyl-4-(3,3,4,5,5-pentametylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 1-(3-((2-((2-klor-4-(3,4-dimetylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)azepan-2-on,
- 15 3-(3-((2-((4-(heksahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,3-oksazepan-2-on,
- 4-(3-((2-((4-(heksahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((2-((4-(oktahydro-2H-pyrido[1,2-a]pyrazin-2-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 20 3-(3-((2-((4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,3-oksazepan-2-on,
- 4-(3-((2-((4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 25 4-(3-((2-((4-(5-metyl-2,5-diazabisyklo [2.2.1]heptan-2-yl)fenyl)amino)-5-(trifluormetyl)-pyridin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 3-(3-((2-((2-brom-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)-amino)propyl)-1,3-oksazepan-2-on,
- 4-(3-((2-((2-metyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)-amino)propyl)-1,4-oksazepan-3-on,
- 30 4-(3-((2-((6-(5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)pyridin-3-yl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,4-oksazepan-5-on,


- 1-(3-((2-((4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)azepan-2-on,
 4-(3-((2-((4-(4-metyl)piperazin-1-yl)-2-(trifluormetyl)fenyl)amino)-5-(trifluormetyl)-pyridin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 5 4-(3-((2-((2-metyl-4-(4-(metylsulfonyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyridin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 3-(3-((2-((2-etyl-4-(4-metyl)piperazine-1-karbonyl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 1-(3-((2-((2-syklopropyl-4-(morfolinometyl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)piperidin-2-on,
 10 3-(3-((2-((2-etyl-4-(2-(pyrrolidin-1-yl)etyl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 3-(3-((2-((2-fluor-4-(3-morfolinopropyl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 15 1-(3-((2-((2-syklopropyl-4-((1,1-dioksidotiomorfolino)metyl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)piperidin-2-on,
 3-(3-((2-((4-(3-(dietyl)amino)propyl)-2-(trifluormetyl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
 4-(3-((2-((2-klor-4-(3,4-dimetyl)piperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyridin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 20 4-(3-((2-((2-metyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 4-(3-((2-((2-klor-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)fenyl)-amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 25 4-(3-((2-((2-metyl-4-((1S,4S)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 4-(3-((2-((2-klor-4-((1S,4S)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 4-(3-((2-((2-metyl-4-((1R,4R)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
 30 4-(3-((2-((2-klor-4-((1R,4R)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,


- 3-(3-((2-((2-klor-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 3-(3-((2-((2-klor-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 5 3-(3-((2-((2-metyl-4-((1S,4S)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 3-(3-((2-((2-klor-4-((1S,4S)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 3-(3-((2-((2-metyl-4-((1R,4R)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 10 3-(3-((2-((2-klor-4-((1R,4R)-5-metyl-2,5-diazabisyklo[2.2.1]heptan-2-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,3-oksazinan-2-on,
- 4-(3-((2-((2-metyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 15 4-(3-((2-((2-klor-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)-pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((2-((2-metyl-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 4-(3-((2-((2-klor-4-((1R,5S)-8-metyl-3,8-diazabisyklo[3.2.1]oktan-3-yl)-fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-3-on,
- 20 4-(3-((2-((4-(4-metylpiperazin-1-yl)-2-(trifluormetoksy)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 4-(3-((2-((2-(difluormetoksy)-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 25 3-(3-((2-((2-syklopropyl-4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-6,6-dimetyl-1,3-oksazinan-2-on,
- 4-(3-((2-((4-((1R,5S)-3,8-diazabisyklo[3.2.1]oktan-3-yl)-2-etyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
- 1-(3-((2-((2-syklopropyl-4-(3-((dimetylamino)metyl)azetidin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)piperidin-2-on,
- 30 4-(3-((2-((4-(3-((dimetylamino)metyl)azetidin-1-yl)-2-etyl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,


4-(3-((2-((4-(4-metylpiperazin-1-yl)fenyl)amino)-5-(trifluormetyl)pyrimidin-4-yl)amino)propyl)-1,4-oksazepan-5-on,
og farmasøytisk akseptable salter, enantiomerer, stereoisomerer, og tautomerer derav.


5


9. Forbindelsen ifølge krav 1 valgt fra gruppen som består av:































































og farmasøytisk akseptable salter derav,
for eksempel hvor forbindelsen er representert av:


(i)



5


eller et farmasøytisk akseptabelt salt derav;

(ii)



eller et farmasøytisk akseptabelt salt derav; eller

(iii)



eller et farmasøytisk akseptabelt salt derav.

- 5 **10.** En farmasøytisk sammensetning som omfatter en forbindelse ifølge et hvilket som helst av krav 1-9, en farmasøytisk akseptabel eksipiens og eventuelt ett eller flere ytterligere terapeutiske midler.
- 11.** Den farmasøytiske sammensetningen ifølge krav 10, hvor et ytterligere
- 10 terapeutisk middel er til stede og er (i) en MAPKAP-veihinhibitor, for eksempel en MEK-inhibitor slik som en MEK-inhibitor valgt fra gruppen som består av trametinib, selumetinib, cobimetinib, binimetinib, og farmasøytisk akseptable salter derav; en ERK-inhibitor slik som en ERK-inhibitor valgt fra gruppen som består av ulixertinib, SCH772984, LY3214996, ravoxertinib, VX-11e, og
- 15 farmasøytisk akseptable salter derav; en RAF-inhibitor slik som en RAF-inhibitor valgt fra gruppen som består av LY3009120, LXH254, RAF709, dabrafenib, vemurafenib, og farmasøytisk akseptable salter derav; eller en Ras-inhibitor, slik som en Ras-inhibitor valgt fra gruppen som består av AMG-510, MRTX849, og farmasøytisk akseptable salter derav; eller (ii) et kjemoterapeutisk middel, slik
- 20 som et kjemoterapeutisk middel valgt fra gruppen som består av anti-tubulin midler, vinorelbin, DNA-alkylerende midler, DNA interkalerende midler, 5-fluoruracil, capecitabin, cytarabin, decitabin, 5-azacytadin, gemcitabin, og metotreksat.
- 25 **12.** En forbindelse ifølge et hvilket som helst av krav 1-9, for anvendelse i behandlingen av en forstyrrelse i en pasient med behov for det.

13. En forbindelse ifølge et hvilket som helst av krav 1-9, for anvendelse i en fremgangsmåte for å behandle en kreftform i en pasient med behov for det, som omfatter å administrere til pasienten en terapeutisk effektiv mengde av forbindelsen.

5

14. Forbindelsen for anvendelsen ifølge krav 13, hvor kreften er valgt fra gruppen som består av gastrointestinale stromale svulster, spiserørskreft, magekreft, melanomer, gliomer, glioblastomer, eggstokk-kreft, blærekreft, bukspyttkjertelkreft, prostata kreft, lungekreft, brystkreft, nyrekreft, leverkreft, osteosarkomer, multiple myelomer, livmorhalskarsinomer, kreft som er metastasert til bein, papillært tyroid karsinom, ikke-småcellet lungekreft, og kolorektal kreft.

15. Forbindelsen for anvendelsen ifølge krav 13 eller krav 14, hvor fremgangsmåten videre omfatter å administrere til pasienten ett eller flere ytterligere terapeutiske midler, for eksempel hvor det ytterligere terapeutiske middelet er (i) en MAPKAP-veihemmer, for eksempel en MEK-inhemmer, slik som en MEK-inhemmer valgt fra gruppen som består av trametinib, selumetinib, cobimetinib, binimetinib, og farmasøytisk akseptable salter derav; en ERK-inhemmer slik som en ERK-inhemmer valgt fra gruppen som består av ulixertinib, SCH772984, LY3214996, ravoxertinib, VX-11e, og farmasøytisk akseptable salter derav; en RAF-inhemmer slik som en RAF-inhemmer valgt fra gruppen som består av LY3009120, LXH254, RAF709, dabrafenib, vemurafenib, og farmasøytisk akseptable salter derav; eller en Ras-inhemmer, slik som en Ras-inhemmer valgt fra gruppen som består av AMG-510, MRTX849, og farmasøytisk akseptable salter derav; eller (ii) et kjemoterapeutisk middel, slik som et kjemoterapeutisk middel valgt fra gruppen som består av anti-tubulin-midler, vinorelbin, DNA-alkylerende midler, DNA-interkalerende midler, 5-fluoruracil, capecitabin, cytarabin, decitabin, 5-azacytadin, gemcitabin, og metotreksat.